David Sallman, MD, Moffitt Cancer Center, Tampa, FL, shares some insights into novel agents and combinations being investigated for the treatment of myelodysplastic syndromes (MDS). Dr Sallman first discusses the promise of venetoclax in combination with hypomethylating agents (HMAs) in patients with MDS, and further highlights the Phase III VERONA trial (NCT04401748). Following this, Dr Sallman comments on the promise of sabatolimab in MDS, clinical trials evaluating the use of this agent, and unmet needs in the field. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.